Presidio Medical is a clinical-stage, privately held medical technology company developing a transformational neuromodulation platform to treat diseases of undesired neural activity.  Their first indication will be chronic pain - a market in which approximately 50 million individuals experience symptoms, resulting in economic costs totaling more than $560 billion dollars each year.